Dexcom Q1 FY26: where the revenue came from and where it went
The whole income statement of Dexcom for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- Apr 30, 2026
Revenue$1.19B
+15% year over year
Gross profit$0.75B
63% margin
Operating profit$0.26B
21% margin
Net profit$0.20B
17% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.19 | 100% | +15% |
| US | 0.83 | 70% | +11% |
| Non US | 0.36 | 30% | +26% |
| Cost of revenue | −0.44 | 37% | |
| Gross profit | 0.75 | 63% margin | +6pp |
| R&D | −0.15 | 12% | −2pp |
| SG&A | −0.35 | 30% | −1pp |
| Operating profit | 0.26 | 21% margin | +9pp |
| Other income, net | 0.01 | ||
| Tax | −0.07 | ||
| Net profit | 0.20 | 17% margin | +7pp |
224 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest